Amgen Stock Drops 4% as Drug Updates Fail to Impress Analysts
Amgen Inc.'s stock dropped 4% after revealing less effective results for two drugs in development: Uplizna for myasthenia gravis...
atopic dermatitis
Organon Buys Roivant’s Dermavant Unit for Up to $1.2B, Expands Dermatology Portfolio
In a groundbreaking deal worth up to $1.2 billion, Organon has agreed to acquire medical dermatology company Dermavant Sciences,...
RAPT Therapeutics Shares Plunge on FDA Study Hold
**Lead:** RAPT Therapeutics faces a crisis as its shares nosedive over 65% following a serious adverse event that led...
RAPT Therapeutics Stock Plummets as FDA Halts Trials
**Lead:** RAPT Therapeutics halts dosing of zelnecirnon in two clinical trials after a patient experiences liver failure, causing shares...
FDA Puts Two RAPT Therapeutics Studies on Hold After Adverse Event
Lead: RAPT Therapeutics faces FDA scrutiny as studies of its zelnecirnon drug candidate are halted due to a severe...
Allakos to Cut Workforce by Half After Lirentelimab Trial Results
Biotechnology company Allakos is cutting its workforce in half and halting activities related to lirentelimab after clinical trials for...
Aldeyra Therapeutics Shares Rise 12% on Positive ADX-629 Trial Results
Shares of Aldeyra Therapeutics surged 12% to $3.31 after the biotechnology company announced positive results from a Phase 2...
Cara Therapeutics Discontinues Clinical Program, Shares Sink
Shares of biopharmaceutical company Cara Therapeutics plummeted by 49% to 63 cents after the company announced it would discontinue...
Almirall Shares Rise on European Approval for Skin Drug
Almirall's shares surged after the European Union approved its Ebglyss drug for atopic dermatitis. The Spanish biopharmaceutical company announced...
Aclaris Therapeutics Shares Plummet on Zunsemetinib Failure
Shares of Aclaris Therapeutics plummeted over 85% in premarket trading today after the company's drug candidate, zunsemetinib, failed to...